Posted by Michael Wonder on 18 May 2021
Sandoz Canada congratulates the Quebec government on implementing a shift towards biosimilars
18 May 2021 - The shift announced by Quebec will follow a similar approach to policies introduced in British Columbia, Alberta and recently in New Brunswick to transition patients who use a reference biologic to a biosimilar.
Sandoz Canada, a leader in generic pharmaceuticals and biosimilars, welcomes the Quebec Government’s shift towards biosimilars.
According to the government’s announcement, this transition will generate annual savings of more than $100 for the public drug insurance plan and its insured parties. These savings will be reinvested in the healthcare system to improve access to innovative drug therapies, in particular.
